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Background/aim: We aimed to analyze the usefulness of such a reserved area for the admission of the patients’ symptoms suggesting
COVID-19 and compare the demographic and clinical characteristics of the patients with COVID-19 and without COVID-19 who were
admitted to C1 during the first month of the COVID-19 outbreak in our hospital.
Materials and methods: A new area was set up in Hacettepe University Adult Hospital to limit the contact of COVID-19 suspicious
patients with other patients, which was named as COVID-19 First Evaluation Outpatient Clinic (C1). C1 had eight isolation rooms
and two sampling rooms for SARS-CoV-2 polymerase-chain-reaction (PCR). All rooms were negative-pressurized. Patients who had
symptoms that were compatible with COVID-19 were referred to C1 from pretriage areas. All staff received training for the appropriate
use of personal protective equipment and were visited daily by the Infection Prevention and Control team.
Results: One hundred and ninety-eight (29.4%) of 673 patients who were admitted to C1were diagnosed with COVID-19 between
March 20, 2020, and April 19, 2020. SARS-CoV-2 PCR was positive in 142 out of 673 patients. Chest computerized tomography (CT)
was performed in 421 patients and COVID-19 was diagnosed in 56 of them based on CT findings despite negative PCR. Four hundred
and ninety-three patients were tested for other viral and bacterial infections with multiplex real-time reverse-transcriptase PCR (RTPCR). Blood tests that included complete blood count, renal and liver functions, d-dimer levels, ferritin, C- reactive protein, and
procalcitonin were performed in 593 patients. Only one out of 44 healthcare workers who worked at C1 was infected by SARS-CoV-2.
Conclusion: A well-planned outpatient care area and teamwork including internal medicine, microbiology, and radiology specialists
under the supervision of infectious diseases specialists allowed adequate management of the mild-to-moderate patients with suspicion
of COVID-19.
Key words: Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019, SARS-CoV-2, COVID-19, outpatient clinic,
Turkey

1. Introduction
The rapid dissemination of novel severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) became a big
challenge for the appropriate management of coronavirus
disease 2019 (COVID-19) [1, 2].The total number of
patients with COVID-19 reached up to 80,794,084 with
1,766,513 deaths on 27 December 20201.The clinical
spectrum of COVID-19 varies from asymptomatic
1

infection to respiratory failure, septic shock, and multiple
organ dysfunction syndromes (MODS) and death [3, 4]. In
a study from Wuhan; 81% of patients had mild disease, 14
% of patients had severe disease, and 5 % had the critical
disease [5].
A large number of the patients who were admitted to
hospitals with suspicion of COVID-19 overcrowded the
emergency rooms (ER), which can lead to delay in the

COVID-19 Coronavirus Pandemic (2021). [online]. Website https://www.worldometers.info/coronavirus/ [accessed 15 April 2021].
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assessment of other emergencies and, also, pose a high
risk for transmission of COVID-19 during triage in the ER
[6]. Setting up a rapid response infrastructure was able to
reduce the workload in the ER [7, 8].
There were 148,817 cases with 4636 deaths around
the world when the first case of COVID-19 was detected
on 11 March 2020 in Turkey and on 21 March 2020 in
Hacettepe University Hospitals1 [9].The spread of SARSCoV-2 in ER is of concern and a new area was set up in
our hospital to limit the contact of COVID-19 suspicious
patients with other patients, which was named COVID-19
First Evaluation Outpatient Clinic (C1). Here, we aimed
to analyze the usefulness of such a reserved area for the
admission of the patients’ symptoms suggesting COVID-19
and compare the demographic and clinical characteristics
of the patients with COVID-19 and without COVID-19
who were admitted to C1 during the first month of the
COVID‐19 outbreak in our hospital.
2. Materials and methods
Hacettepe University Adult Hospital is a 730-bed tertiary
care center in Ankara, the capital city of Turkey. C1
was established at Hacettepe University Adult Hospital
immediately after the detection of the first cases in
Turkey. Any patient who was admitted to the hospital
was questioned for COVID-19 symptoms and history of
contact with a COVID-19 patient at the pretriage areas
located at the entrances of the hospital. In case of suspicion
for COVID-19, patients were referred to C1. This area was
previously used as ER and replaced by the new ER two
and a half years ago. C1 consisted of eight single-patient
rooms and two sampling rooms, which were all negativepressurized (Figure). Rooms were periodically checked for
air pressure by construction and technical services.
Patients who were suspected of COVID-19 according
to the World Health Organization (WHO) and the
Turkish Ministry of Health COVID-19 guidelines were
taken into the sampling room2. Vital signs were checked
before sampling. Hypoxic (pO2 < 93 at ambient air) and
tachypneic (respiratory rate > 22/min) patients were
referred to the ER. A combined oropharyngeal and
nasopharyngeal sample was taken by a doctor for SARSCoV-2 real-time reverse-transcriptase–polymerase-chainreaction (RT-PCR) and a blood sample was taken by
the nurse in another room if requested by the attending
physician according to the clinical presentation and local
guideline. Viral nucleic acid isolation from the samples
was achieved by using Bio-Speedy vNAT viral nucleic acid
buffer (Bioeksen R&D Technologies Ltd, Turkey). SARSCoV-2 RT-PCR kit (Bioeksen R&D Technologies Ltd,
Turkey) was used for the diagnosis in our hospital. The

results were available on the same day. Multiplex RT-PCR
was performed by using the Allplex Respiratory Panel
(Seegene, South Korea) to detect other respiratory viral
and bacterial infections.
Chest computerized tomography (CT) was performed
at the area reserved for COVID-19 patients in the radiology
unit which was localized just behind the C1. Patients
were followed up in the solitary rooms until results were
obtained. Appropriate personal protective equipment
for aerosol-generating procedures was used either
during sampling or examining the patients according
to the instructions. Sampling rooms were cleaned and
then disinfected by hydrogen peroxide between each
patient after every procedure. Patients with suspicion of
COVID-19 were hospitalized in the wards reserved for
COVID-19 or discharged for home isolation according to
the local guidelines. The hospitalization criteria were as
follows; age higher than 50 years, presence of comorbid
diseases such as diabetes mellitus, chronic pulmonary
diseases, hypertension, cancer, stem cell or solid organ
transplantation, detection of pneumonia, increase in
lactate dehydrogenase (LDH), C-reactive protein (CRP),
neutrophil-to-lymphocyte ratio (NLR), D-dimer, ferritin,
cardiac enzymes, and acute renal failure (Supplementary
Table 1). Electrocardiography (ECG) was performed if
antiviral therapy with hydroxychloroquine (HQ) was
prescribed for those who were followed up at home
isolation (Supplementary Table 2).
A total of 20 physicians, 12 nurses, and 12 housekeeping
staff worked at C1.The staff worked in three shifts which
consisted of 8 or 16 h. Four physicians, 4 (2 at night shifts)
nurses, and 3 (2 at night shifts) housekeeping staff worked
at each shift. The resting period was 16 or 24 h. A team
of physicians from various medical departments took part
in the evaluation of patients. All of the C1 staff received
training about the appropriate use of personal protective
equipment and as well as about the local guideline for
the initial management of COVID-19. All procedures
were performed under the leadership and supervision of
infectious diseases specialists. The outpatient clinic was
available 24 h a day including the weekends. All healthcare
workers were monitored daily for any symptom suggesting
COVID-19, and SARS-CoV-2 RT-PCR was performed in
case of suspicion of COVID-19. However, there was no
routine laboratory-based screening policy for healthcare
workers including C1 staff to detect possible asymptomatic
cases except close contacts of the patients with COVID-19.
The characteristics of the patients who were admitted
to C1 between March 20, 2020, and April 19, 2020,
were evaluated, retrospectively. Demographic data such
as age, sex, occupation as being a healthcare worker,

T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü COVID-19 (SARS-CoV-2 Enfeksiyonu) Rehberi Bilim Kurulu Çalışması, 25 Mart 2020 (2020).
[online]. Website https://hastane.deu.edu.tr/images/hastanemizden-haberler/corona/COVID-19_Rehberi_25.03.2020.pdf [accessed 1 April 2021]
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Figure. COVID-19 First Evaluation Clinic.

Figure. COVID-19 First Evaluation Clinic
Table 1. Comparison of demographic characteristics of the patients who were admitted to “C1 First Evaluation Clinic”.
All patients
(N: 673)

Proven and probable
COVID-19 (N: 198)

Without COVID-19
(N: 475)

p-value

Age (years)
Median (min–max)

35 (18-90)

38 (19–77)

35 (18-90)

0.002**

Gender n (%)
Male

317 (47.1)

94(47.5)

223 (46.9)

0.901***

Sex n (%)
Female

356 (52.9)

104 (52.5)

252 (53.1)

0.901***

Healthcare worker
n (%)

308 (45.8)

82 (41.4)

226 (47.6)

0.144***

Current smoking
n (%)

145 (21.5)

44 (28.9)

History of contact with a diagnosed
COVID-19 case n (%)

381(56.6)

134 (67.7)

247 (52)

0.001***

Chronic obstructive pulmonary
disease n (%)

212 (31.5)

68 (34.3)

144 (30.3)

0.305***

Hypertension n (%)

45 (6.7)

10 (5.1)

35 (7.4)

0.273***

Diabetes mellitus
n (%)

31 (4.6)

8 (4)

23 (4.8)

0.651***

Solid malignancy n (%)

17 (2.5)

6 (3)

11 (2.3)

0.590***

Hematological malignancy n (%)

3 (0.4)

0 (0)

3 (0.6)

0.262***

Chronic heart disease n (%)

27 (4)

10 (5.1)

17 (3.6)

0.375***

Characteristic

101 (35.7)

0.167***

Italics represent statistically significant results. Median (min–max) was given. **Mann–Whitney U test***Pearson’s chi-square/Fisher’s
exact test were used.
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Table 2. Comparison of symptoms of the patients who were diagnosed with COVID-19 with those of the patients in whom COVID-19
was ruled out.
All patients
(N: 673)

Proven and probable
COVID-19 (N:198)

Without COVID-19
(N:475)

p-value

316 (47)

102 (51.5)

214 (45.1)

0.126***

Cough (%)

456 (67.8)

145 (73.2)

311 (65.5)

0.050***

Myalgia/arthralgia (%)

192(28.5)

84 (42.4)

108 (22.7)

0.001***

Sore throat (%)

167 (24.8)

39 (19.7)

128 (26.9)

0.047***

Loss of smell and/or taste (%)

23 (3.4)

13 (6.6)

10 (2.1)

0.004***

Runny nose (%)

23 (3.4)

8 (4)

15 (3.2)

0.566***

Dyspnea (%)

178 (26.4)

51 (25.8)

127 (26.7)

0.793***

Diarrhea (%)

46 (6.8)

12 (6.1)

34 (7.2)

0.607***

Symptoms
Fever (body temperature ≥ 37.5°C) (%)

Italics represent statistically significant results. ***Pearson’s chi-square/Fisher’s exact test was used.

comorbidities, clinical signs, or symptoms and contact
history with a confirmed COVID-19 case were recorded.
The results of complete blood count (CBC), coagulation
parameters, liver and renal functions, CRP, procalcitonin
(PCT), LDH, and creatine kinase levels which were
performed according to the local guidelines were extracted
from the hospital database.
The case identification was based on PCR results and
radiological findings. Patients with a positive SARS-CoV-2
PCR were identified as proven COVID-19, patients with
clinical symptoms with a positive chest CT were identified
as probable COVID-19, and patients who had an alternative
diagnosis with a negative SARS-CoV-2 PCR and/or chest
CT were grouped as non-COVID-19 patients.
Patients with COVID-19 (proven and probable
patients) were compared with non-COVID-19 patients
in terms of demographic and clinical characteristics.
Categorical variables were presented as numbers and
percentages. Continuous variables were given as mean and
standard deviation (SD) if normally distributed, median
and minumm–maximum (min–max) if nonnormally
distributed. Categorical variables were compared using
the Pearson chi-square test/Fisher’s exact test. Continuous
variables were compared using the Student’s t-test or Mann–
Whitney U test according to the distribution of variables.
p-values less than 0.05 were considered statistically
significant. For all statistical analyses, IBM SPSS Statistics
24 v17.0 (IBM Corp. Chicago, IL, USA) software was used.
The study was approved by the Institutional NonInterventional Clinical Research Ethics Committee,
Ankara, Turkey.
3. Results
The median age of the patients was 35 years. Patients with
COVID-19 were older than non-COVID-19 patients (38

4

vs 35 years, p = 0.002). Three hundred fifty-six (52.9
%) patients were female and 308 (45.8 %) patients were
healthcare workers (Table 1). A total of 198 (29.4%) of 673
patients who were admitted to C1 were diagnosed with
COVID-19. SARS-CoV-2 PCR was positive in 142 (71.7%)
of 198 patients.
Hypertension and diabetes mellitus were the most
common comorbid diseases. Three hundred eighty-one
(56.6%) patients had a history of contact with a COVID-19
patient. Contact history was more common in patients
with COVID-19 (67.7% vs 52%, p = 0.001). Cough (73.2%
vs 65.5, p = 0.05), myalgia/arthralgia (42.4% vs 22.7%, p =
0.001), and loss of smell and/or taste (6.6% vs 2.1%) were
more common in COVID-19 patients, and sore throat was
more common in non-COVID-19 patients (26.9% vs 19.7,
p = 0.047). The rates of fever, dyspnea, diarrhea, and runny
nose during admission were similar in the two groups
(Table 2).
Lymphocytopenia, thrombocytopenia, and high
ferritin levels were more common in patients with
COVID-19. CRP levels were higher in patients with
COVID-19 than non-COVID-19 patients (p = 0.001), and
PCT levels were lower in patients with COVID-19 than
non-COVID-19 patients (p = 0.011) (Table 3).
A chest X-ray was performed in 518 patients, and chest
CT was performed in 421 (62.6%) patients. Pneumonia
was detected at the chest CT of 139 patients and the chest
X-ray of 5 patients. SARS-CoV-2 PCR was positive in 83
(59.71%) of 139 patients who had a chest CT that was
reported as compatible with COVID-19 pneumonia. All of
the patients who had an X-ray compatible with COVID-19
pneumonia had also positive SARS-CoV-2 PCR.
Multiplex PCR for other viral pathogens were found
to be positive in 27 (7.7%) of non-COVID-19 patients
while only two (1.3%) of 152 patients with COVID-19 (p
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Table 3. Comparison of laboratory findings of the patients who were diagnosed with COVID-19 with those of patients in whom
COVID-19 was ruled out.
Laboratory findings

All patients

Proven and probable
COVID-19

Without COVID-19

Lymphocyte count mm3
(mean ± SD)(N: 571)

1866 ± 1035
(571)

1401 ± 608
(191)

2100 ± 1124
(380)

0.001*

Thrombocyte count mm3
(mean ± SD) (N: 571)

221,207 ± 60,459
(571)

196,073 ± 49,773
(191)

233,839 ± 61,458
(380)

0.001*

C-reavtive protein mg/dl
Median (min–max) (N: 423)

0.65(0.03–34.6)
(423)

0.94(0.1–24.2)
(159)

0.47(0.03–34.6)
(264)

0.001**

Procalcitonin ng/ml
Median (min–max) (N: 296)

0.02 (0–1.95)
(296)

0.03 (0.01–0.67)
(158)

0.02 (0–1.95)
(138)

0.011**

Ferritin µg
Median (min- max) N: 353)

51 (2.4–1901)
(353)

57.7 (2.4–1901)
(165)

43.85(2.6–1036.2)
(188)

0.016**

Lactate dehydrogenase IU/l
Median (min–max) (N: 299)

182 (79–4041)
(299)

188 (79–4041)
(156)

180 (103–1106)
(143)

0.135**

Creatine kinase IU/l
Median (min–max) (N: 272)

91(2–3249)
(272)

91(2–3249)
(147)

88 (15–1031)
(125)

0.513**

D-dimer (mg/L)
(mean ± SD) (N: 383)

0.6 ± 1.32
(383)

0.67 ± 1.79
(171)

0.54 ± 0.75
(212)

0.331*

Alanine aminotransferase IU/L
Median (min–max) (N: 325)

20(7–244)
(325)

20(8–244)
(167)

20.5 (7–210)
(158)

0.749**

Creatinine mg/dL
Median (min–max) (N: 394)

0.71(0.35–7.41)
(394)

0.7(0.37–1.96)
(176)

0.72(0.35–7.41)
(218)

0.335**

Positive respiratory virus panel (%)
(N: 504)

29 (5.75)
(504)

2 (1.3)
(152)

27 (7.7)
(352)

0.005***

Positive respiratory bacterial panel (%)
(N: 493)

96 (19.47)
(493)

26 (17.3)
(150)

70 (20.4)
(343)

0.428***

p-value

Italics represent statistically significant results. Mean ± SD and median (min–max) were given. *Student’s t-test, **Mann–Whitney U test,
***Pearson’s chi-square/Fisher’s exact test were used.

= 0.005). The rate of positive multiplex PCR for bacterial
pathogens was similar between patients with COVID-19
and non-COVID-19 patients (Table 3). The most
common bacteria that was detected in multiplex PCR was
Haemophilus influenza and, the most common virus was
rhinovirus (Table 4).
Two hundred and six (30.61 %) of the patients who were
admitted to C1 were hospitalized at COVID-19 wards; 162
(24.07 %) of these were diagnosed with COVID-19. In 44
(6,54%) of 206 patients, COVID-19 was ruled out after
hospitalization. Thirty-six (5.35 %) patients were followed
up as outpatient [10]. Hydroxychloroquine (HQ) was
given as monotherapy to patients with symptoms without
pneumonia. Patients with pneumonia were treated with
a combination of HQ plus azithromycin as inpatients.
Nonsteroidal antiinflammatory drugs or paracetamol

were prescribed for fever. Antibiotics were administered
for 16 patients with COVID-19 in whom pneumonia was
detected at chest CT. CRP levels were significantly higher
in these patients (p = 0.001). The 22 out of 673 patients
who received an antibacterial treatment had higher CRP
and PCT levels when compared with the patients who did
not receive antibacterial treatment (Table 5).
A total of 673 SARS-CoV-2 RT-PCR tests were
performed in our hospital from March 20, 2020 to April
19, 2020.Three hundred and eight of these tests were
performed for healthcare personnel who had symptoms
compatible with COVID-19 or exposed to COVID-19
patients without appropriate personal protective
equipment.
Eighty-two (41.4 %) of 198 patients that were diagnosed
with COVID-19 were healthcare personnel. COVID-19
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Table 4. Distribution of multiplex PCR results, antimicrobial treatment choices, C-reactive protein, and procalcitonin
levels of the patients who were admitted to “C1 First Evaluation Clinic”.
COVID-19 with pneumonia
(n: 144)

COVID-19 without
pneumonia (n: 54)

Non-COVID-19
(n: 475)

Bacterial multiplex PCR

n: 123

n: 28

n: 342

Haemophilus influenzae

10 (8.13 %)

4 (14.3 %)

47 (13.74 %)

Streptococcus pneumoniae

6 (4.88 %)

2 (7.14 %)

14 (4.1 %)

Haemophilus influenza and
Streptococcus pneumoniae

2 (1.63 %)

-

7 (2.05 %)

Mycoplasma pneumoniae

1 (0.81 %)

-

-

Chlamydia pneumoniae

1 (0.81 %)

-

1 (0.3 %)

Chlamydia pneumoniae and
Streptococcus pneumoniae

-

-

1 (0.3 %)

Total

20 (16.27 %)

6 (21.43 % )

70 (20.47 %)

Viral multiplex PCR

Performed in 124 patients

Performed in 28 patients

Performed in 353 patients

Human rhinovirus

-

-

13 (3.68 %)

Adenovirus

1 (4.2 %)

-

6 (1.7 %)

Influenza B

-

1 (3.57 %)

5 (1.42 %)

Parainfluenza 2

-

-

1 (0.28 %)

RSV*-A

-

-

1 (0.28 %)

RSV*-B

-

-

1 (0.28 %)

Total

1 (4.2 %)

1 (3.57 %)

27 (7.65 %)

Hydroxychloroquine sulfate

5 (3.5 %)

41 (75.9 %)

Hydroxychloroquine sulfate plus
azithromycin

127 (88.2 %)

3 (5.56 %)

-

Oseltamivir

83 (57.64 %)

10 (18.52 %)

24 (5.05 %)

Antiviral treatment

*Respiratory syncytial virus
was diagnosed in only one out of 44 staff who worked
at C1.This was an internist who reported to have close
contact with two internists who were the first COVID-19
patients at our hospital.
4. Discussion
Immediately after detection of COVID-19 in Turkey, the
first evaluation outpatient clinic was set up to avoid the
chaos which can occur with the increase in the number of
cases. The separate area for the evaluation of the patients
with suspicion of COVID-19 became an important
advantage at our hospital in terms of preventing the spread
of SARS-CoV-2 infection, detailed medical investigation of
all patients who were admitted to C1 and timely diagnosis
and management of COVID-19 patients.
The 45.8% of 673 patients who were admitted to C1
were healthcare workers. The risk of COVID-19 is high

6

in healthcare workers due to repeated exposures with
COVID-19 patients; however, the rate of COVID-19 was
not higher in healthcare workers than in the other people
who were admitted to C1 during the first month of the
pandemic at our hospital. The concerns about the disease
and encouraging policy to seek medical investigation for
COVID-19 as early as possible can have a role in the high
number of admissions by healthcare workers. According
to the local hospital instructions, any healthcare worker
who had symptoms that can be related to COVID-19 was
strongly recommended to admit to C1 for evaluation.
Advanced age is considered an important risk factor
for COVID-19 [7, 11]. In a study from Wuhan, the median
age of the patients with COVID-19 was reported as
60 years, ranging from 18 to 95 years, and 38.3% of the
patients were older than 65 years [11]. Similar findings
were reported by a retrospective cohort study from France
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Table 5. Comparison of procalcitonin and C-reactive protein levels according to receipt of antibacterial treatment.
Patients who received
antibiotics (n = 22)

Patients who did not receive
antibiotics (n = 651)

p-value

Procalcitonin (ng/mL) Median (min–max)

0.45 (0.01–0.67)

0.02 (0–1.95)

0.002**

C Reactive Protein (mg/dL) Median (min–max)

3.25 (0.21–24.2)

0.61 (0.03–34.6)

0.001**

Italics represent statistically significant results. Median (min–max) was given **Mann–Whitney U test.
which included 89,530 patients [12]. Although the patients
with COVID-19 who were diagnosed at C1 during the first
month of the pandemic were younger when compared
with other countries [13, 14], the patients with COVID-19
were older than patients without COVID-19 (38 years vs
35 years, p = 0.002). The curfew for people who were older
than 65 years was probably the main reason which limited
the spread of COVID-19 in elderly patients during the first
month of the pandemic in Turkey.
The presence of comorbid diseases can influence
the outcome of COVID-19 patients. In a metaanalysis,
hypertension was the most prevalent comorbid disease
with a rate of 21.1% of 1576 patients. Diabetes mellitus,
cardiovascular disease, and respiratory system disease
were the other common comorbidities in 9.7%, 8.4%, and
1.5% of the patients, respectively [15]. Thirty-one point
five percent of the patients who were admitted to C1 had
comorbid diseases, and the most common diseases were
diabetes mellitus and hypertension, as observed in the
previous studies. Although chronic diseases were detected
more in patients with COVID-19, no statistically significant
difference was detected between the two groups.
Fever, cough, diarrhea, headache, and dyspnea were
the most common clinical symptoms in a metaanalysis
that included 45 studies [16]. The rates of cough, myalgia/
arthralgia, sore throat, and loss of smell or/and taste
were more prevalent in patients with COVID-19, and
the presence of these symptoms should trigger SARSCoV-2 PCR. Our local guideline recommended chest CT
for patients with comorbid diseases and/or respiratory
symptoms (cough, fever, etc.) in suspicion of COVID-19.
A total of 421 chest CTs were performed and this approach
allowed to diagnose 56 patients whose SARS-CoV-2 PCR
tests were negative but CT findings were concordant with
COVID-19. In a recent study, bronchoalveolar lavage fluid
was found as positive for SARS-CoV-2 PCR in 18 patients
who had two negative consecutive PCR tests performed
from a nasopharyngeal swab. Chest CT scans were
compatible with COVID-19 in those patients [17].
High D-dimer levels and lymphopenia were reported
to be related to poor outcomes [18-20]. We were able to
test CBC in 571 patients and D-dimer in 353 patients.
Lymphocyte and platelet counts were found to be

statistically significantly lower in those diagnosed with
COVID-19 compared to those who were not. D-dimer
values did not differ between the two groups but ferritin
values were found to be significantly higher in patients
with COVID-19.
Fever is a common symptom of respiratory tract
infections. Forty-seven percent of 673 patients who were
admitted to C1 had a fever. It is important to rule out
bacterial infections in patients presenting with respiratory
symptoms and fever. We were able to request multiplex PCR
for bacterial respiratory pathogens in 493 patients. Ninetysix of 493 PCR tests were reported as positive. However, the
rate of positivity of the multiplex PCR panel for respiratory
bacterial pathogens was not significantly different in
patients with COVID-19 when compared with nonCOVID-19 patients (%17.3 vs %20.4, p = 0.428). The most
commonly detected bacterial pathogen was H. influenza
in 12 patients with COVID-19. A recent metaanalysis that
included 24 studies reported that 3.5% of the patients with
COVID-19 had a bacterial coinfection. The rate was highly
variable as 0% to 42%. However, 71.9% of patients with
COVID-19 received antibiotics in the same analysis [21],
while 10.6% out of 198 patients with COVID-19 received
an antibacterial agent in our cohort. A total of 130 out of
198 patients with COVID-19 received azithromycin in our
cohort. One can speculate that azithromycin use should be
regarded as antibacterial therapy for possible communityacquired bacterial pneumonia. However, in our hospital
it was used in combination with hydroxychloroquine
as a part of COVID-19 treatment according to Turkish
Ministry of Health treatment guidelines2. In a study from
Italy, overall antibiotic consumption in March–April
2020 was not different from that in the prepandemic
period but it was found that the mean consumption of
levofloxacin and ceftriaxone was as high as azithromycin
which was not the case in our hospital [22]. Nevertheless,
use of unnecessary antibiotics including azithromycin
can influence the antibacterial resistance and should be
avoided [23]. The reason for the low rate of prescribing
antibiotics targeting community-acquired pneumonia
such as respiratory quinolones or ceftriaxone can be rapid
access to SARS-CoV-2 PCR and chest CT on the same day
of admission. Multiplex PCR for bacterial pathogens was
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reported usually in 2 days. Patients who had a positive
bacteria PCR result but did not receive empirical antibiotics
were reevaluated by infectious diseases specialists. In case
of resolution of the symptoms, antibacterial therapy was
not recommended. Evaluation of clinical, radiological,
and microbiological results together resulted in a more
adequate antibiotic usage.
The biomarkers such as CRP and PCT can also guide
to initiate antibiotics while waiting for PCR results and
they have been widely investigated in the differential
diagnosis of community-acquired pneumonia and sepsis,
previously [24, 25]. The mean CRP and PCT values of
the patients who received antibacterial agents were found
to be significantly higher than the patients who did not
receive antibiotics (Table 5). However, mean CRP levels
were higher in patients with COVID-19. High CRP levels
were reported in patients with COVID-19 and reported to
be related to poor prognosis [18-20]. In the patients who
were admitted to C1, mean CRP levels were significantly
higher in COVID-19 patients with pneumonia when
compared with COVID-19 patients without pneumonia
(3.0543 ± 4.379 vs 0.9103 ± 1.662, p = 0.001). This may
reflect disease severity as previously reported [26]. PCT
was measured in 296 patients at admission and PCT values
were found to be significantly higher in patients without
COVID-19.
In a recent guideline about using antibacterial
therapy in patients with COVID-19; routine antibacterial
treatment is not recommended. Antibacterial treatment is
recommended if radiological findings and inflammatory
markers are compatible with bacterial coinfection
[27]. However, the findings of our study showed that
interpretation of the biomarker levels is not quite easy
and the role of CRP and PCT can be limited for the
differential diagnosis of COVID-19 with other respiratory
infections. Furthermore, well-planned studies are required
to understand the role of biomarkers to guide antibacterial
treatment in this setting.
Other viral infections can mimic COVID-19. Multiplex
PCR for viral respiratory pathogens can be useful. Twentynine of 503 PCR tests for viral pathogens were positive. The
rate of positive PCR for viral pathogens was significantly
higher in patients without COVID-19. Coinfection with
COVID-19 was observed in only two patients. Human
rhinovirus was the most common agent detected in the
viral panel. Since the influenza season was still going on,
influenza B was the other common pathogen. Adenovirus,
RSV, and parainfluenza were the other viruses detected in
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the viral panel. Coinfection with another virus has been
rarely reported in patients with COVID-19 and rhinovirus
was reported as the most frequent virus in patients with a
negative SARS-CoV-2 PCR [28]. During the early days of
the pandemic in Turkey, coinfection with influenza was of
concern. A high rate of patients who were admitted to C1
received oseltamivir and the rate of oseltamivir treatment
was higher in patients with COVID-19 (93 (47 %) vs 24
(5.05 %), p = 0.001).
In a study from a tertiary care university hospital from
Turkey that investigated the risk factors for transmission
of COVID-19 among healthcare workers; infection rate of
healthcare workers who worked in COVID-19 units was
significantly higher than those who did not (8.3% vs 3.4%
p = 0.027) [31]. Only one out of 44 healthcare workers who
worked at C1 was diagnosed with COVID-19. Similarly,
in a hospital in South Korea that had a reserved area for
COVID-19 patients like C1, transmission of SARS-CoV-2
between healthcare workers and patients was not detected
[8]. Hand hygiene, using of appropriate personal protective
equipment, monitoring of patients in isolated single rooms
and, implementation of cleaning and disinfection in all
rooms after each patient protected healthcare workers as
well as patients from COVID-19 transmission. Beside the
well-designed physical infrastructure, it is important to
keep the working hours of the staff optimal to maintain
the compliance with safe working instructions in a highrisk area.
5. Conclusions
Early diagnosis of infected patients and ensuring adequate
isolation are very important to control the spread of
COVID-19. The purpose of setting up the COVID-19
first evaluation outpatient clinic was to prevent the
overcrowding of ER due to mild or moderate infections,
ensure appropriate distancing and isolation, and enable
emergency services to serve for real emergencies. A wellplanned outpatient care area and teamwork including
internal medicine, microbiology, and radiology specialists
under the supervision of infectious diseases specialists
allowed adequate management of the mild-to-moderate
patients with suspicion of COVID-19.
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